The Ready Lab is engaged in the discovery and synthesis of biologically active small molecules. We focus equally on natural products and synthetic compounds emerging from high-throughput screening efforts. For examples of specific projects, see our publications page.
Synthetic studies on natural products are guided by an interest in novel approaches to polycyclic skeletons. Target selection is influenced by both issues of molecular complexity and biological activity.
Additionally, we collaborate with biologists at UT Southwestern, and elsewhere, to discover small molecules with promising biological activity using high-throughput screening strategies. We are involved in efforts to identify small molecules with relevance to neurodegenerative diseases, cancer, and infectious disease.
In these efforts we work with clinicians, pharmacologists, and biologists to develop drug-like compounds through proof-of-concept stages in animal models of disease. Both classes of chemicals – natural products and synthetic compounds – are often discovered using unbiased phenotypic screening.
Accordingly, our synthetic efforts are directed at providing tools to facilitate mode-of-action studies such as photo-crosslinking probes and reagents for affinity chromatography. In the course of target-directed synthetic projects, we often exploit the opportunity to develop novel reagents or transformation.
Current research is directed toward the discovery of novel cycloadditions and catalytic C-C cross-coupling reaction. We anticipate that the combination of these efforts will greatly expand the power of organic chemistry and enable the rapid and efficient synthesis of valuable complex molecules.